HUNTSVILLE, Ala., April 12, 2012 /PRNewswire-FirstCall/ -- Qualitest Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Levetiracetam Oral Solution, 100mg/mL. Qualitest plans to begin distribution in mid-2012.
The total sales for Levetiracetam Oral Solution, 100mg/mL, in the U.S. for the 12 months ending Dec. 31, 2011, were approximately $62.2 million, according to IMS Health.
Founded in 1983, Qualitest provides affordable, high-quality generic pharmaceuticals. Featuring a current portfolio exceeding 600 products, the company has grown significantly since its inception and is now ranked in the top ten among all suppliers of generics, based on total prescriptions filled. Qualitest is an operating company of Endo Pharmaceuticals Holdings Inc. (Nasdaq: ENDP), a U.S.-based, diversified healthcare company that is redefining healthcare value by finding solutions for the unmet needs of patients along care pathways for pain management, pelvic health, urology, endocrinology and oncology. Learn more at (www.endo.com).
SOURCE Qualitest Pharmaceuticals